According to data and analytics company GlobalData’s latest survey, UK healthcare professionals believe that the UK will not be an attractive destination for healthcare research and manufacturing following Brexit. The report, Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018, found that only 23 per cent of healthcare professionals surveyed across the US, UK and EU thought that the UK would be an attractive destination for healthcare companies to conduct research and manufacturing after Brexit. Of the UK healthcare professionals surveyed, 83 per cent said the country will not be an attractive destination for healthcare research and manufacturing after Brexit.
“Sentiment on this question has potentially been affected by the considerable amount of negative press associated with Brexit’s likely impact on the healthcare sector over the past three months. Stories such as the NHS requiring drug makers to stockpile drugs in preparation for a 'no-deal' Brexit and pharma companies like Sanofi and Novartis increasing medicine stockpiles, and AstraZeneca halting UK investments over Brexit uncertainties likely played a part in negatively affecting industry professional’s confidence in the UK,” said Alexandra Annis, MS, Managing Healthcare Analyst at GlobalData.